Abstract
Levosimendan is a K+-ATPase activator, cardiac myofilament Ca2+sensitizer, and phosphodiesterase inhibitor with positive inotropic effects and vasodilatory properties in the pulmonary and systemic circulation, all of which are potential therapeutic targets for patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).1 In the recent multicenter, double-blind, placebo-controlled Hemodynamic Evaluation of Levosimendan in Patients with HFpEF (HELP) study, a weekly infusion of levosimendan decreased the pulmonary capillary wedge pressure (PCWP) and central venous pressure, and was associated with a significant increase in 6-minute walk distance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
